Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00613028 · ClinicalTrials.gov registry record · Phase 2
Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00613028 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 23 participants.
The verdict
NCT00613028, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
Primary objective To estimate 6-month progression free survival probability of pts w recurrent GBM treated w bev + either daily temozolomide/etoposide following progression on bev + irinotecan Secondary Objectives To evaluate safety \& tolerability of bev + either daily temozolomide/etoposide among pts w recurrent GBM who have progressed on bev + irinotecan To evaluate radiographic response, progression free survival \& overall survival of pts w recurrent GBM treated w bev + either daily temozolomide/etoposide following progression on bev + irinotecan
Interventions
- DRUG Temo + Avastin
- DRUG VP-16 + Avastin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2008-04 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00613028
The ClinicalTrials.gov registry entry for NCT00613028 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Temo + Avastin is the first listed.
NCT00613028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00613028 about?
NCT00613028 is a clinical study titled "Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan". Primary objective To estimate 6-month progression free survival probability of pts w recurrent GBM treated w bev + either daily temozolomide/etoposide following progression on bev + irinotecan Secondary Objectives To evaluate safety \& tolerability of bev + either daily temozolomide/etoposide among ...
What is the current status of trial NCT00613028?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2008-04. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00613028?
The interventions under investigation include: Temo + Avastin (DRUG), VP-16 + Avastin (DRUG).
Who is sponsoring clinical trial NCT00613028?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.